Flyer - German Cancer Research Center

WelcomeDear Colleagues,The immune system plays an important role duringtumor development and progression. Cellular immuneresponses can be very powerful as seen in transplantrejection or graft versus host disease.Therapeutic strategies utilizing tumor directed cellularimmune responses are still experimental, whereasantibody based therapies are already standard of carein many tumor entities.The Helmholtz Alliance on Immunotherapy of Cancerand the National Center for Tumor Diseases (NCT)Heidelberg have gathered many of the world wideleading experts on T lymphocyte physiology, immunodeficiency and lymphocyte based tumor therapy toreflect the current understanding of tumor immunologyand discuss future therapeutic strategies.We are happy to welcome you to our symposium on19 th – 20 th November, 2009 in the beautiful city ofHeidelberg to hear about the latest development anddiscuss critical issues of Immunotherapy and Immunodeficiency.Dirk JägerDirector Medical Oncology,NCT HeidelbergChristoph von KalleDirector Translational Oncology,NCT HeidelbergPeter KrammerDivision of Immunogenetics,DKFZ HeidelbergStefan MeuerInstitute for Immunology,University Heidelberg

DirectionsLocation of the Lecture Hallof the German CancerResearch Center.German Cancer ResearchCenter, Lecture HallIm Neuenheimer Feld 280,69120 Heidelberg, Germany

Thursday, November 19 th , 20098:15 WelcomeWiestler, Otmar D.Immunodeficiencies andgene therapy IChair: Williams, David; von Kalle, Christof8:30 Clinical presentation, classification and genetics ofcommon variable immuno deficiencyPeter, Hans-Hartmut9:00 Severe combined immunodeficiency: from molecularimmunology to therapyCavazzana-Calvo, Marina9:30 Gene therapy for combined immunodeficiencies:from preclinical to clinical studiesAiuti, Alessandro10:00 Update on gene therapies for SCIDThrasher, Adrian10:30 Gene therapy for HIV:lessons learned and future decisionsSymonds, Geoff11:00 CoffeeImmunodeficiencies andgene therapy IIChair: Cavazzana-Calvo, Marina ; Peter, Hans-Hartmut11:30 Gene therapy of chronic granulomatous disease:lessons, chances and challengesGrez, Manuel12:00 The clonal repertoire of the gene-modified humanimmune systemvon Kalle, Christof12:20 Novel genetic defects of immunity – from moleculardiagnosis to gene therapyKlein, Christoph12:50 Hematopoietic cell gene therapy for X-linkedadrenoleukodystrophyCartier, Nathalie

Thursday, November 19 th , 200913:20 Improving safety and efficacy of gene therapy bylentiviral vectorsNaldini, Luigi13:50 LunchMechanisms and targets inimmunotherapy IChair: Greenberg, Philip D.; Krammer, Peter15:00 The utility of induced pluripotent stem cellsin treatment of genetic blood diseasesWilliams, David15:30 Molecular pathways in Notch-dependent acutelymphoblastic T cell leukemiavon Boehmer, Harald16:00 Regulatory T cells for immune tolerance andtumor immunitySakaguchi, Shimon16:30 Cancer immunoediting: mechanistic insights andtherapeutic implicationsSchreiber, Robert17:00 No escapeBlankenstein, Thomas17:20 CoffeeMechanisms and targets inimmunotherapy IIChair: Allison, James; Jäger, Dirk17:50 Tumor stroma and immune responseSchreiber, Hans18:20 Melanoma genetics – implications fortumor immunogenicity and immunotherapySchadendorf, Dirk18:40 Regulation of T cell responses against cancerBeckhove, Phillip19:00 End

Friday, November 20 th , 2009Pathways of therapeutic interventionChair: Melief, Cornelis; Kirkwood, John8:15 Resistance and sensitivity towards induction ofapoptosisKrammer, Peter8:35 The role of IL-15 in the life and death of lymphocytes:implications for cancer therapy and vaccine designWaldmann, Thomas9:05 Immunological side effects of MAP kinase inhibitorsfor the recognition of tumor cells by cytotoxic T cellsand NK cellsFalk, Christine9:25 Dendritic cell priming of high avidity allorestricted,peptide-specific T cellsSchendel, Dolores9:45 Acute hepatitis C – presentation and managementManns, Michael10:05 CoffeeT cell therapyChair: Huber, Christoph; Meuer, Stefan10:30 Adoptive transfer of natural Treg cells in stem celltransplantationEdinger, Matthias11:00 Allogeneic immunotherapy of hematologic malignanciesStorb, Rainer11:30 New aspects of the GVL reactionKolb, Hans-Jochem11:50 New approaches for adoptive T cell transfer astreatment for hematological malignancies uponbone marrow transplantationO´Reilly, Richard12:20 Development of effective T cell adoptive cancerimmunotherapiesRobbins, Paul

Friday, November 20 th , 200912:50 T cell recognition of tumors: creating responsesthat can be effective in vivoGreenberg, Phillip13:30 LunchNovel strategies in immunotherapyChair: Schendel, Dolores; von Boehmer, Harald14:30 Systemic therapy of melanomaKirkwood, John15:00 Targeting cancer stem cellsCebon, Jonathan15:30 Overview of the cancer vaccine collaborativeinternational clinical trials programGnjatic, Sacha16:00 Peptide-based vaccines for the immunotherapyof melanomaRomero, Pedro16:30 Strategies for immunotherapy of established diseasecaused by high risk human papilloma virusesMelief, Cornelis17:00 CoffeeClinical interventionChair: Schreiber, Robert; Storb, Rainer17:30 Checkpoint blockade in immunotherapyAllison, James18:00 Targeting dendritic cells in vivo – a novel approachto cure cancerEnk, Alexander18:20 A novel paradigm for cancerGalon, Jerome18:50 Characterization of anti-tumor immune responses:implication for treatment decisionsJäger, Dirk19:10 End

Speakers and ChairpersonsAiuti, AlessandroMD, PhD, San Raffaele Telethon Institute for Gene Therapy,Milan; ItalyAllison, JamesPhD, Institute for Immunology,Memorial Sloan-Kettering Cancer Center, New York; USABeckhove, PhilippMD, Research Group Translational Immunology,German Cancer Research Center, Heidelberg; GermanyBlankenstein, ThomasPhD, Department of Molecular Immunology and Gene Therapy,Max-Delbrück-Centrum, Berlin; GermanyCartier, NathalieMD, PhD, INSERM, Hôpital Saint Vincent de Paul, Paris; FranceCavazzana-Calvo, MarinaMD, PhD, Department of Biotherapy at Necker Children’s Hospital,Paris; FranceCebon, JonathanMD, Ludwig Institute for Cancer Research, Melbourne Centre forClinical Sciences – Cancer Vaccine Laboratory; AustraliaEdinger, MatthiasMD, Department of Haematology and Oncology,University Hospital Regensburg; GermanyEnk, AlexanderMD, Department of Dermatology, University Hospital Heidelberg;GermanyFalk, ChristinePhD, Translational Oncology, National Center for Tumor Diseases(NCT) Heidelberg and Institute for Immunology, UniversityHeidelberg; Germany

Speakers and ChairpersonsGalon, JeromePhD, Cordeliers Research Centre, INSERM Paris; FranceGnjatic, SachaPhD, Ludwig Institute for Cancer Research atMemorial Sloan-Kettering Cancer Center, New York; USAGreenberg, Philip D.MD, PhD, Fred Hutchinson Cancer Research Center, Seattle; USAGrez, ManuelPhD, Georg-Speyer-Haus Frankfurt,Institute for Biomedical Research; GermanyHuber, ChristophMD, Department of Internal Medicine III, University Medical Centerof the Johannes Gutenberg University Mainz; GermanyJäger, DirkMD, Medical Oncology, National Center forTumor Diseases (NCT) Heidelberg; GermanyKirkwood, JohnMD, Division of Hematology/Oncology,University of Pittsburgh, Medical Center; USAKlein, ChristophMD, PhD, Department of Pediatric Hematology, Oncology,Hannover Medical School; GermanyKolb, Hans-JochemMD, Medizinische Klinik und Poliklinik III,Klinikum der Universität München-Großhadern; GermanyKrammer, PeterMD, Division Immunogenetics,German Cancer Research Center, Heidelberg; Germany

Speakers and ChairpersonsManns, MichaelMD, Department of Gastroenterology, Hepatology and Endocrinology,Centre for Internal Medicine, Hannover Medical School; GermanyMelief, CornelisMD, PhD, Department of Immunohematology andBlood Transfusion, Leiden University; NetherlandsMeuer, StefanMD, Institute for Immunology, University Heidelberg; GermanyNaldini, LuigiMD, PhD, San Raffaele Telethon Institute for Gene Therapy,Milan; ItalyO´Reilly, RichardMD, Department of Pediatrics,Memorial Sloan-Kettering Cancer Center, New York; USAPeter, HartmutMD, Department of Rheumatology and Clinical Immunology,University Hospital Freiburg; GermanyRobbins, PaulPhD, Tumor Immunology Section,National Cancer Institute, Bethesda; USARomero, PedroMD, Ludwig Institute for Cancer Research,Lausanne Branch; SwitzerlandSakaguchi, ShimonMD, PhD, Institute for Frontier Medical Sciences,Kyoto University; JapanSchadendorf, DirkMD, Department of Dermatology, Venerology and Allergology,University of Essen, Medical Center; Germany

Speakers and ChairpersonsSchendel, DoloresPhD, Institute of Molecular Immunology,Helmholtz-Zentrum München; GermanySchreiber, HansMD, PhD, Department of Pathology, University of Chicago; USASchreiber, RobertPhD, Department of Pathology & Immunology,Washington University – School of Medicine; USAStorb, RainerMD, Transplantation Biology Program,Fred Hutchinson Cancer Research Center, Seattle; USASymonds, GeoffPhD, Calimmune Inc., Sydney; AustraliaThrasher, AdrianMD, PhD, University College London, Institute of Child Health;United Kingdomvon Boehmer, HaraldMD, PhD, Laboratory of Lymphocyte Biology,Dana Farber Cancer Institute, Boston; USAvon Kalle, ChristofMD, PhD, Translational Oncology, National Center forTumor Diseases (NCT) Heidelberg; GermanyWaldmann, ThomasMD, Cytokine Immunology and Immunotherapy Section,National Cancer Center, Bethesda; USAWiestler, Otmar D.MD, Chairman and Scientific Director;German Cancer Research Center, Heidelberg; GermanyWilliams, DavidMD, Div. Hematology/Oncology, Children`s Hospital Boston; USA

Information and ContactDate:November 19 th – 20 th , 2009Location:Lecture HallGerman Cancer Research Center (DKFZ)Im Neuenheimer Feld 28069120 Heidelberg, GermanyInformation and Registration:Dr. Astrid BeiglböckCoordinator of the Medical Oncology at the NationalCenter for Tumor Diseases (NCT) HeidelbergIm Neuenheimer Feld 35069120 Heidelberg, GermanyPhone: +49 (0) 6221 56-6904Fax: +49 (0) 6221 56-7225E-mail: astrid.beiglboeck@nct-heidelberg.deOnline-Registration:http://immunotherapy.nct-meeting.deRegular fee 250 €Reduced rate 125 € (PhD Students, Students)